Targeting CD19 in diffuse large B-cell lymphoma : An expert opinion paper
Bailly, Sarah (Département d'Hématologie. Cliniques Universitaires Saint-Luc)
Cartron, Guillaume (Centre Hospitalier Universitaire de Montpellier)
Chaganti, Sridhar
Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz)
Corradini, Paolo (University of Milan)
Düll, Johannes (Medizinische Klinik und Poliklinik II. Universitätsklinikum Würzburg)
Ferrarini, Isacco (Department of Medicine. Section of Hematology. University of Verona)
Osborne, Wendy (Newcastle Upon Tyne Hospitals NHS Foundation Trust)
Rosenwald, Andreas (University of Würzburg)
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Tilly, Hervé (Centre Henri Becquerel and University of Rouen)
Van Den Neste, Eric (Cliniques Universitaires Saint-Luc)
Viardot, Aandreas (University Hospital of Ulm (Alemanya))
Visco, Carlo (University of Verona)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
Note:	Medical writing assistance was provided by Sarah Stowell of Alligent Europe (Envision Pharma Group), funded by Incyte Biosciences International Sàrl.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Hematological Oncology, Vol. 40 Núm. 4 (october 2022) , p. 505-517, ISSN 1099-1069

DOI: 10.1002/hon.3013
PMID: 35488888

13 p, 463.3 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles